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Background:  Transthyretin (TTR) cardiac amyloidosis is an under-recognized form of cardiomyopathy caused by the deposition of 
liver-derived mutant and/or wild-type (WT) TTR in the myocardium resulting in heart failure and death. The hereditary form, known as 
familial amyloidotic cardiomyopathy (FAC), is most frequently associated with the V122I TTR genotype, which is present in ~4 of African-
Americans. There are currently no approved therapies. ALN-TTRsc is a subcutaneously administered investigational RNA interference 
therapeutic comprised of a small interfering RNA targeting both mutant and wild-type TTR mRNA. The therapeutic hypothesis is that 
lowering of serum TTR protein may prevent cardiac amyloid deposition and result in clinical benefit.
methods:  This open-label study was undertaken to evaluate ALN-TTRSC in patients (pts) with TTR cardiac amyloidosis. Eligible pts must 
have biopsy-proven mutant or WT TTR cardiac amyloidosis, stable heart failure, NYHA class ≤3, 6-MWD ≥150 m. Pts receive ALN-TTRSC 
5 or 7.5 mg/kg SC daily x 5, followed by 5 weekly doses (through Day 35). The purpose of the study is to evaluate safety and PD, and 
explore clinical activity of TTRSC through 6-MWT; NYHA classification; CMR and echocardiography; cardiac biomarkers; KCCQ; modified 
BMI; and EQ-5D QOL in pts with TTR cardiac amyloidosis.
results:  As of July 21st 2014, 18 pts have been enrolled. Baseline characteristics include: 12 pts with senile systemic amyloidosis (SSA) 
and 6 pts with FAC (5 V122I, 1 T60A); median age 71 years; mean 6-MWD 411 m; mean NT-proBNP 2459 pg/mL; mean interventricular 
septum thickness 18 mm (range 16 - 22) and preserved LVEF (50%). Three, 13 and 2 pts were NYHA class I, II and III, respectively. Serum 
TTR lowering was > 85% and comparable between dose groups and between SSA and FAC. The most common adverse events were low 
incidence of mild and transient injection site reactions. Cardiac biomarkers and imaging parameters available for 10 pts showed disease 
stability at Days 42 and 90.
conclusion:  ALN-TTRSC was well-tolerated and resulted in mean serum TTR reduction of > 80% in both FAC and SSA pts. Additional 
safety, PD and clinical data through Day 90 for a total of 26 pts will be presented.
